

## P&T Motion History Antidepressants

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
<b>SSRI:</b> citalopram escitalopram fluoxetine fluvoxamine paroxetine sertraline vilazodone vortioxetine  <b>SNRI/SSNRI:</b> desvenlafaxine duloxetine levomilnacipran venlafaxine  <b>OTHER:</b> bupropion mirtazapine nefazodone <i>trazadone</i>	After considering the evidence of safety, efficacy and special populations for their FDA approved indications, I move that bupropion, citalopram, duloxetine, escitalopram, fluoxetine, sertraline, fluvoxamine, levomilnacipran, mirtazapine, paroxetine, desvenlafaxine, venlafaxine, vortioxetine and vilazodone are safe and efficacious for their approved indications. The Washington Preferred Drug List must include as preferred at least two SSRIs one of which must have an indication for pediatric and adolescent use, at least one SNRI or SSNRI, mirtazapine, and bupropion. The second generation antidepressants cannot be subject to therapeutic interchange in the Washington preferred drug list.  Nefazodone is also efficacious for its approved indications but does have a higher risk of hepatic toxicity and so should not be a preferred drug on the PDL.  Motion: Schwilke 2 <sup>nd</sup> : Flatebo	December 15, 2021	Yes Lee Park	Yes Lee Schwilke	Passed unanimous

**Bold = new this update**

**Grey italic = not part of PDL program**

12/16/2021